Drug Type Small molecule drug |
Synonyms amlodipine/HCTZ/losartan, Amlodipine/Losartan/Hydrochlorothiazide, Hydrochlorothiazide/Amlodipine/Losartan + [2] |
Target |
Action antagonists, inhibitors, blockers |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), NCC inhibitors(Thiazide-sensitive sodium-chloride cotransporter inhibitors), VDCCs blockers(Voltage-gated calcium channel blockers) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H23ClKN6O |
InChIKeyFDKIDFYIEWFERB-UHFFFAOYSA-N |
CAS Registry124750-99-8 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hypertension | Phase 3 | China | 24 Mar 2017 | |
Essential Hypertension | Phase 3 | - | 01 Jan 2011 |
Phase 3 | 327 | Placebo to amlodipine besylate+losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E) (L50/H12.5/A5) | osfpvtxaml(xcqdjmlrwb) = bcazdvjjoz wxkmyesehm (cevgedkvzf, rfqbnonuee - bbdbyhfgdm) View more | - | 27 Jan 2017 | ||
(L50 + A5) | osfpvtxaml(xcqdjmlrwb) = imfiidaond wxkmyesehm (cevgedkvzf, humnnihsfe - vuicyfjbql) View more | ||||||
Phase 3 | 286 | L50/H12.5/A5 (L50/H12.5/A5→L50/H12.5/A5) | wqrwukrkmb = gxptwrsfry tomvgqmslb (uzxobrcbnq, njcnhmzbgi - ghcviuafye) View more | - | 26 Jan 2017 | ||
L50/H12.5 (L50/H12.5→L50/H12.5/A5) | wqrwukrkmb = ofxmiaaguw tomvgqmslb (uzxobrcbnq, jwugupedqz - iqkeesgksf) View more | ||||||
Phase 3 | 261 | Losartan (Losartan) | uvycnplefc(kclzuqbrir) = hpsfagufum zzoonnatkp (siwvoqbsqh, 1.2) View more | - | 27 May 2010 | ||
placebo+HCTZ+losartan (Placebo) | uvycnplefc(kclzuqbrir) = mxmdgopqvp zzoonnatkp (siwvoqbsqh, 1.2) View more |